CL2007002836A1 - Compuestos derivados de 1,3,5-triazina o pirimidina, inhibidores de quinasa; composicion farmaceutica; y uso para tratar una enfermedad mediada por quinasa, tal como cancer. - Google Patents

Compuestos derivados de 1,3,5-triazina o pirimidina, inhibidores de quinasa; composicion farmaceutica; y uso para tratar una enfermedad mediada por quinasa, tal como cancer.

Info

Publication number: CL2007002836A1
Authority: CL; Chile
Prior art keywords: triazine; pyrimidine; kinase; cancer; treat
Prior art date: 2006-10-02

Application number

CL200702836A

Other languages

English (en)

Inventor

Pamela A Xie Yongping Albaugh

Original Assignee

Irm Llc Y Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-02

Filing date

2007-10-02

Publication date

2008-05-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38955203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007002836(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-10-02 Application filed by Irm Llc Y Novartis Ag filed Critical Irm Llc Y Novartis Ag

2008-05-23 Publication of CL2007002836A1 publication Critical patent/CL2007002836A1/es

Links

JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
108091000080 Phosphotransferase Proteins 0.000 title 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
102000020233 phosphotransferase Human genes 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Psychiatry (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)

CL200702836A 2006-10-02 2007-10-02 Compuestos derivados de 1,3,5-triazina o pirimidina, inhibidores de quinasa; composicion farmaceutica; y uso para tratar una enfermedad mediada por quinasa, tal como cancer. CL2007002836A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US82787306P	2006-10-02	2006-10-02

Publications (1)

Publication Number	Publication Date
CL2007002836A1 true CL2007002836A1 (es)	2008-05-23

Family

ID=38955203

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702836A CL2007002836A1 (es)	2006-10-02	2007-10-02	Compuestos derivados de 1,3,5-triazina o pirimidina, inhibidores de quinasa; composicion farmaceutica; y uso para tratar una enfermedad mediada por quinasa, tal como cancer.

Country Status (22)

Country	Link
US (1)	US8202876B2 (es)
EP (1)	EP2057146A1 (es)
JP (1)	JP5153777B2 (es)
KR (1)	KR101101675B1 (es)
CN (2)	CN101522661A (es)
AR (1)	AR063099A1 (es)
AU (1)	AU2007305016B2 (es)
BR (1)	BRPI0719797A8 (es)
CA (1)	CA2663366C (es)
CL (1)	CL2007002836A1 (es)
CO (1)	CO6180440A2 (es)
CR (1)	CR10670A (es)
EA (1)	EA015751B1 (es)
IL (1)	IL197724A0 (es)
MA (1)	MA30772B1 (es)
MX (1)	MX2009003456A (es)
NO (1)	NO20091759L (es)
PE (1)	PE20080828A1 (es)
SM (1)	SMAP200900020A (es)
TN (1)	TN2009000105A1 (es)
TW (1)	TW200823200A (es)
WO (1)	WO2008042639A1 (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0720003A2 (pt)	2006-12-08	2018-09-18	Hoffmann La Roche	pirimidinas substituídas e seu uso como moduladores de jnk
WO2009012221A1 (en) *	2007-07-13	2009-01-22	Board Of Regents, The University Of Texas System	Heterocyclic modulators of cannabinoid receptors
JP5379690B2 (ja) *	2007-09-28	2013-12-25	武田薬品工業株式会社	５員複素環化合物
WO2009111278A2 (en) *	2008-02-29	2009-09-11	Array Biopharma Inc.	Raf inhibitor compounds and methods of use thereof
US20110003859A1 (en) *	2008-02-29	2011-01-06	Array Biopharma Inc.	N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
CA2716947A1 (en) *	2008-02-29	2009-09-11	Array Biopharma Inc.	Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
AR072657A1 (es) *	2008-02-29	2010-09-15	Genentech Inc	Compuestos inhibidores de raf y metodos para su uso
WO2009158432A2 (en)	2008-06-27	2009-12-30	Amgen Inc.	Ang-2 inhibition to treat multiple sclerosis
EP2324008B1 (en)	2008-07-24	2012-05-09	Nerviano Medical Sciences S.R.L.	3,4-diarylpyrazoles as protein kinase inhibitors
CA2760778A1 (en) *	2009-05-13	2010-11-18	Amgen Inc.	Heteroaryl compounds as pikk inhibitors
JO3002B1 (ar)	2009-08-28	2016-09-05	Irm Llc	مركبات و تركيبات كمثبطات كيناز بروتين
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP6150813B2 (ja)	2011-11-11	2017-06-21	ノバルティスアーゲー	増殖性疾患の治療方法
CA2856406C (en)	2011-11-23	2020-06-23	Novartis Ag	Pharmaceutical formulations
SG11201406584TA (en) *	2012-04-24	2014-11-27	Vertex Pharma	Dna-pk inhibitors
CA2876689C (en)	2012-06-13	2022-04-26	Incyte Corporation	Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
RS62649B1 (sr)	2013-03-12	2021-12-31	Vertex Pharma	Inhibitori dnk-pk
PH12015502383B1 (en)	2013-04-19	2023-02-03	Incyte Holdings Corp	Bicyclic heterocycles as fgfr inhibitors
AU2014293013A1 (en)	2013-07-26	2016-03-17	Race Oncology Ltd.	Combinatorial methods to improve the therapeutic benefit of bisantrene
KR102411227B1 (ko) *	2013-10-17	2022-06-21	버텍스 파마슈티칼스 인코포레이티드	Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
SI3057959T1 (en) *	2013-10-17	2018-07-31	Vertex Pharmaceuticals Incorporated	DNA-PK INHIBITORS
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (en)	2015-02-20	2024-02-27	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016161268A1 (en)	2015-04-01	2016-10-06	Enanta Pharmaceuticals, Inc.	Hepatitis b antviral agents
WO2016164754A1 (en) *	2015-04-09	2016-10-13	Eisai R&D Management Co., Ltd.	Fgfr4 inhibitors
US10738035B2 (en)	2015-05-13	2020-08-11	Enanta Pharmaceuticals, Inc.	Hepatitis B antiviral agents
WO2017011552A1 (en)	2015-07-13	2017-01-19	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
US10301255B2 (en) *	2015-07-22	2019-05-28	Enanta Pharmaceuticals, Inc.	Hepatitis B antiviral agents
WO2017066193A1 (en)	2015-10-15	2017-04-20	Princeton Drug Discovery, Llc	Novel inhibitors of protein kinases
WO2017136403A1 (en)	2016-02-02	2017-08-10	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
KR102398439B1 (ko)	2016-03-07	2022-05-16	이난타 파마슈티칼스, 인코포레이티드	B형 간염 항바이러스제
EP3468561A4 (en)	2016-06-10	2019-12-04	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
MX394860B (es)	2016-09-27	2025-03-24	Vertex Pharma	Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
JP6778833B2 (ja) *	2017-01-20	2020-11-04	深▲チェン▼市塔吉瑞生物医薬有限公司ＳｈｅｎｚｈｅｎＴａｒｇｅｔＲｘ，Ｉｎｃ．	キナーゼ活性を抑制するための（ヘテロ）アリールアミド類化合物
CN108602800B (zh) *	2017-01-20	2019-08-27	深圳市塔吉瑞生物医药有限公司	用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SG11202001685TA (en)	2017-08-28	2020-03-30	Enanta Pharm Inc	Hepatitis b antiviral agents
US10723733B2 (en)	2017-12-06	2020-07-28	Enanta Pharmaceuticals, Inc.	Hepatitis B antiviral agents
WO2019113173A1 (en)	2017-12-06	2019-06-13	Enanta Pharmaceuticals, Inc.	Hepatitis b antiviral agents
WO2019141957A1 (en)	2018-01-19	2019-07-25	Cado Biotechnology Ivs	N-pyrimidinyl hydroxy pyrazole derivatives and uses thereof
US11058678B2 (en)	2018-01-22	2021-07-13	Enanta Pharmaceuticals, Inc.	Substituted heterocycles as antiviral agents
US10729688B2 (en)	2018-03-29	2020-08-04	Enanta Pharmaceuticals, Inc.	Hepatitis B antiviral agents
RS66310B1 (sr)	2018-05-04	2025-01-31	Incyte Corp	Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko)	2018-05-04	2026-04-23	인사이트 코포레이션	Fgfr 억제제의 염
TW202024093A (zh)	2018-09-21	2020-07-01	美商安塔製藥公司	作為抗病毒劑之官能化雜環
EP3883570A4 (en)	2018-11-21	2022-07-13	Enanta Pharmaceuticals, Inc.	FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
WO2020247444A1 (en)	2019-06-03	2020-12-10	Enanta Pharmaceuticals, Inc,	Hepatitis b antiviral agents
US11472808B2 (en)	2019-06-04	2022-10-18	Enanta Pharmaceuticals, Inc.	Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2020247561A1 (en)	2019-06-04	2020-12-10	Enanta Pharmaceuticals, Inc,	Hepatitis b antiviral agents
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021007488A1 (en)	2019-07-11	2021-01-14	Enanta Pharmaceuticals, Inc.	Substituted heterocycles as antiviral agents
WO2021055425A2 (en)	2019-09-17	2021-03-25	Enanta Pharmaceuticals, Inc.	Functionalized heterocycles as antiviral agents
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en)	2019-10-14	2024-10-10	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
MX2022006691A (es)	2019-12-04	2022-09-19	Incyte Corp	Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
WO2021113479A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US11802125B2 (en)	2020-03-16	2023-10-31	Enanta Pharmaceuticals, Inc.	Functionalized heterocyclic compounds as antiviral agents
CA3196620A1 (en)	2020-10-05	2022-04-14	Enliven Therapeutics, Inc.	5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
EP4323405A1 (en)	2021-04-12	2024-02-21	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
US20240208935A1 (en) *	2021-04-21	2024-06-27	The Regents Of The University Of California	Compositions and methods for treating neurodegenerative diseases
WO2022255778A1 (ko)	2021-06-01	2022-12-08	주식회사 에즈큐리스	Ｉｌ-33 단백질 저해용 화합물의 스크리닝 방법 및 상기 화합물을 포함하는 알러지성 질환 치료용 약학조성물
TW202313610A (zh)	2021-06-09	2023-04-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之三環雜環
CA3220274A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2023158795A1 (en) *	2022-02-18	2023-08-24	Accent Therapeutics, Inc.	Inhibitors of rna helicase dhx9 and uses thereof
WO2024159094A1 (en) *	2023-01-27	2024-08-02	Enliven Inc.	Pyrimidinyl (hetero)aromatic aminopyridine compounds for inhibition of raf kinases
CN122580300A (zh)	2024-01-11	2026-08-14	浙江海正药业股份有限公司	磺酰胺类衍生物及其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3575130D1 (de) *	1984-05-12	1990-02-08	Fisons Plc	Antiinflammatorische 1,n-diarylpyrazol-3-amine, deren zusammensetzungen und verfahren zu deren herstellung.
US6979686B1 (en) *	2001-12-07	2005-12-27	Pharmacia Corporation	Substituted pyrazoles as p38 kinase inhibitors
US6087381A (en)	1997-05-22	2000-07-11	G. D. Searle & Company	Pyrazole derivatives as p38 kinase inhibitors
WO2001030154A2 (de)	1999-10-25	2001-05-03	Basf Aktiengesellschaft	Pyrazole enthaltende agrochemische zusammensetzungen und ihre verwendung als fungizide flanzenschutzmittel
GB0215844D0 (en)	2002-07-09	2002-08-14	Novartis Ag	Organic compounds
AR042052A1 (es)	2002-11-15	2005-06-08	Vertex Pharma	Diaminotriazoles utiles como inhibidores de proteinquinasas
AR042067A1 (es)	2002-11-27	2005-06-08	Bayer Pharmaceuticals Corp	Derivados de anilinopirazol utiles en el tratamiento de la diabetes
US20050014753A1 (en) *	2003-04-04	2005-01-20	Irm Llc	Novel compounds and compositions as protein kinase inhibitors
ATE455546T1 (de) *	2003-08-06	2010-02-15	Vertex Pharma	Aminotriazol-verbindungen als proteinkinase- hemmer
CA2551948A1 (en)	2004-01-09	2005-07-28	Novartis Ag	Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
JPWO2006008874A1 (ja) *	2004-05-21	2008-05-01	萬有製薬株式会社	アミノチアゾ−ル骨格を有するＣｄｋ４、６選択的阻害剤
MXPA06014247A (es) *	2004-06-10	2007-03-12	Irm Llc	Compuestos y composiciones como inhibidores de la proteina quinasa.
PT1791830E (pt) *	2004-09-17	2011-04-04	Vertex Pharma	Compostos de diaminotriazole úteis como inibidores de proteína-quinase
TW200639163A (en)	2005-02-04	2006-11-16	Genentech Inc	RAF inhibitor compounds and methods
US7566716B2 (en)	2005-05-20	2009-07-28	Array Biopharma Inc.	Imidazopyrazines as Raf inhibitor compounds
DE102005036126A1 (de)	2005-07-26	2007-02-01	Carl Zeiss Industrielle Messtechnik Gmbh	Sensormodul für einen Tastkopf eines taktilen Koordinatenmessgerätes
CA2620425A1 (en) *	2005-08-31	2007-03-08	Bayer Healthcare Llc	Anilinopyrazole derivatives useful for the treatment of diabetes
AU2006284751A1 (en)	2005-09-01	2007-03-08	Array Biopharma Inc.	Raf inhibitor compounds and methods of use thereof
CA2643066A1 (en)	2006-03-16	2007-09-20	Pfizer Products Inc.	Pyrazole compounds
WO2007129195A2 (en)	2006-05-04	2007-11-15	Pfizer Products Inc.	4-pyrimidine-5-amino-pyrazole compounds

2007
- 2007-09-24 AU AU2007305016A patent/AU2007305016B2/en not_active Ceased
- 2007-09-24 US US12/444,129 patent/US8202876B2/en not_active Expired - Fee Related
- 2007-09-24 EA EA200970347A patent/EA015751B1/ru not_active IP Right Cessation
- 2007-09-24 JP JP2009531524A patent/JP5153777B2/ja not_active Expired - Fee Related
- 2007-09-24 MX MX2009003456A patent/MX2009003456A/es active IP Right Grant
- 2007-09-24 CN CNA2007800368577A patent/CN101522661A/zh active Pending
- 2007-09-24 CA CA2663366A patent/CA2663366C/en not_active Expired - Fee Related
- 2007-09-24 KR KR1020097006724A patent/KR101101675B1/ko not_active Expired - Fee Related
- 2007-09-24 EP EP07814982A patent/EP2057146A1/en not_active Withdrawn
- 2007-09-24 CN CN201310581142.7A patent/CN103739595A/zh active Pending
- 2007-09-24 BR BRPI0719797A patent/BRPI0719797A8/pt not_active Application Discontinuation
- 2007-09-24 WO PCT/US2007/079340 patent/WO2008042639A1/en not_active Ceased
- 2007-10-02 AR ARP070104361A patent/AR063099A1/es unknown
- 2007-10-02 CL CL200702836A patent/CL2007002836A1/es unknown
- 2007-10-02 PE PE2007001326A patent/PE20080828A1/es not_active Application Discontinuation
- 2007-10-02 TW TW096136908A patent/TW200823200A/zh unknown
2009
- 2009-03-19 IL IL197724A patent/IL197724A0/en unknown
- 2009-03-19 CR CR10670A patent/CR10670A/es not_active Application Discontinuation
- 2009-03-27 SM SM200900020T patent/SMAP200900020A/it unknown
- 2009-03-27 TN TN2009000105A patent/TN2009000105A1/fr unknown
- 2009-04-02 MA MA31753A patent/MA30772B1/fr unknown
- 2009-04-02 CO CO09034040A patent/CO6180440A2/es not_active Application Discontinuation
- 2009-05-04 NO NO20091759A patent/NO20091759L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PE20080828A1 (es)	2008-08-12
BRPI0719797A2 (pt)	2017-10-24
WO2008042639A1 (en)	2008-04-10
CR10670A (es)	2009-05-13
CN103739595A (zh)	2014-04-23
KR20090060322A (ko)	2009-06-11
EA015751B1 (ru)	2011-12-30
MA30772B1 (fr)	2009-10-01
CA2663366A1 (en)	2008-04-10
KR101101675B1 (ko)	2011-12-30
BRPI0719797A8 (pt)	2017-12-26
AR063099A1 (es)	2008-12-30
TN2009000105A1 (en)	2010-08-19
CN101522661A (zh)	2009-09-02
JP5153777B2 (ja)	2013-02-27
US20100029605A1 (en)	2010-02-04
SMAP200900020A (it)	2009-05-11
EP2057146A1 (en)	2009-05-13
NO20091759L (no)	2009-07-01
CA2663366C (en)	2012-02-07
MX2009003456A (es)	2009-04-14
US8202876B2 (en)	2012-06-19
TW200823200A (en)	2008-06-01
IL197724A0 (en)	2009-12-24
AU2007305016B2 (en)	2011-11-03
JP2010505862A (ja)	2010-02-25
EA200970347A1 (ru)	2009-10-30
CO6180440A2 (es)	2010-07-19
AU2007305016A1 (en)	2008-04-10

Publication	Publication Date	Title
CL2007002316A1 (es)	2008-02-01	Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
CL2007003226A1 (es)	2008-02-08	Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
CL2007003495A1 (es)	2008-05-30	Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
BRPI0818804A2 (pt)	2015-04-22	Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
CL2007002017A1 (es)	2008-06-13	Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
CL2008000403A1 (es)	2008-08-18	Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.
CL2007002640A1 (es)	2008-06-20	Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002642A1 (es)	2008-07-18	Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002649A1 (es)	2008-04-11	Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes.
CL2009000576A1 (es)	2009-06-19	Un compuesto {1-etilsulfonil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo o su sal; inhibidor de jak; composicion farmaceutica; y su uso para tratar artritis reumatoide.
CL2007003756A1 (es)	2008-08-22	Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2008000197A1 (es)	2008-08-01	Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2008002243A1 (es)	2009-08-21	Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
DK3567035T3 (da)	2022-09-05	N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
BRPI0815979A2 (pt)	2017-06-13	compostos e composições com inibidores de quinase, bem como uso dos mesmos
DK2004641T3 (da)	2011-01-24	HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
IL197933A (en)	2015-02-26	Knaase inhibitors, pharmaceuticals containing them and their uses
CL2008002130A1 (es)	2009-01-02	Compuestos derivados de 2-amino-cromen-4-ona; composicion farmaceutica que lo comprende; y uso en el tratamiento de una enfermedad que es aliviada por la inhibicion de la proteina quinasa dependiente de adn (adn-pk), tal como cancer.
CL2007000161A1 (es)	2008-05-30	Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
BRPI0917119A2 (pt)	2015-11-17	composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação.
DK1945631T3 (da)	2012-10-22	4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
CL2007000918A1 (es)	2008-02-08	Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
CL2007002578A1 (es)	2008-07-04	Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.